- France and South Korea launch €15M AI-biotech funding call targeting 30 longevity projects.
- Grants up to €500K fund projects, with awards by September 2026.
- AI accelerates drug discovery 40% faster per Nature Biotechnology (2025).
Key Takeaways
- France and South Korea launch €15M AI-biotech funding call targeting 30 longevity projects.
- Grants reach €500K each, with awards by Q3 2026.
- AI speeds drug discovery 40% versus traditional methods (Nature Biotechnology, 2025, n=48 models).
France and South Korea launched the €15M AI-biotech funding call on April 13, 2026. This initiative funds 30 projects blending AI with biotech for longevity research. Applications opened on ANR and MSIT sites and close June 30, 2026.
€15M AI-Biotech Funding Splits €7.5M Per Nation
France commits €7.5 million. South Korea matches it. Organizers plan 30 awards, each capped at €500,000 over two years.
South Korea's Minister Lee Jong-ho announced the call. "AI transforms biotech data into actionable longevity insights," Lee stated at the Seoul launch.
Projects must integrate AI tools like machine learning for protein folding (AlphaFold3, DeepMind 2024) or neural networks detecting senescence markers in human fibroblasts.
AI Speeds Senolytic Drug Discovery 40%
AI models predict senolytic efficacy 40% faster than traditional screening. A Nature Biotechnology study (2025, DOI:10.1038/s41587-025-00012-3; n=48 compounds, p<0.001) validated this in human cell lines.
South Korean teams apply AI to gut microbiome datasets from 5,000-person aging cohorts (Korean Genome Project). They identify longevity-linked taxa with 92% accuracy.
France develops AI-biomarker platforms. Diffusion models simulate cellular aging trajectories, refining senomorphic formulations (tested in C. elegans, n=1,200; human validation pending Phase I).
Eric Topol, Director of Scripps Research Translational Institute, endorsed the call. "Public AI-biotech funding de-risks high-stakes longevity plays," Topol told Wired (April 2026).
VC Lags Behind €15M Government AI-Biotech Funding
Biotech VCs invested $12 billion in AI startups during 2025 (Bloomberg, January 15, 2026). Yet longevity remains underfunded at 8% of total.
France's Minister Sylvie Retailleau highlighted ROI. "Each €1 invested returns €4 in healthspan gains," Retailleau said, citing EU health economic models.
Governments bridge gaps. France and South Korea aim for 15% of global AI-biotech patents by 2030 (WIPO projections). This call follows Altos Labs' $3 billion raise (2022), now valued at $11 billion (PitchBook Q1 2026).
AI Powers Targeted Longevity Interventions
AI personalizes Zone 2 training using HRV data from wearables. A Lancet Digital Health RCT (2024, n=250 athletes, 12 weeks) boosted VO2max 15% (p<0.01) versus standard protocols.
Machine learning scans PubMed for rapamycin analogs. Models predict mTOR inhibition with 85% precision (Cell Metabolism, 2025; validated in mouse models, lifespan +12%).
Korean teams optimize red light therapy (850nm) via skin autofluorescence. Pilot data (n=120 seniors) shows 22% wrinkle reduction (Journal of Photochemistry, 2026).
French consortia decode sleep polysomnography from trackers. They link circadian disruptions to telomere attrition (Aging Cell, 2025 cohort study, n=3,400; HR=1.8 for short sleep).
Robust Tech Stack Bolsters AI-Biotech Funding Projects
Teams leverage PyTorch 2.3 or TensorFlow 2.16. Google Cloud and Naver provide €2 million in compute credits.
Datasets span UK Biobank (500K genomes) and Korean Genome Project (75K exomes). Blockchain via Hyperledger secures sharing; tokenized IP unlocks €50 million private co-funding.
No human trials funded directly—focus stays on preclinical AI models and Phase 0 biomarkers.
Streamlined Application for AI-Biotech Funding
Applicants submit via joint ANR-MSTI portal by June 30, 2026. Expert panels review in July; awards announce September 15, 2026.
SMEs, universities, and NGOs qualify. France-South Korea consortia earn priority. Budgets cover compute (40%), labs (30%), personnel (30%); overhead maxes 20%.
Key Milestones Shape Longevity Outcomes
Teams submit mid-term reports in 2027. Final outcomes due 2029, including peer-reviewed papers and IP filings.
This €15M AI-biotech funding call cements France-South Korea leadership. It seeds scalable longevity breakthroughs, drawing $100M+ private follow-on by 2028.
